Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
about
Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccineImmunoinformatics comes of ageThe effect of recombination on the reconstruction of ancestral sequencesAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesAncestral ReconstructionCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinMapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step studyReconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 ProteinsProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.An evaluation of phylogenetic methods for reconstructing transmitted HIV variants using longitudinal clonal HIV sequence data.Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques.Coping with viral diversity in HIV vaccine design.HIV-1 group M conserved elements vaccine.Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.HIV-1 vaccine development after STEP.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesTemporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody responseThe genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission.Siglecs facilitate HIV-1 infection of macrophages through adhesion with viral sialic acids.Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchangeSubtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120Characterization of a putative ancestor of coxsackievirus B5.HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaquesChallenges in the design of a T cell vaccine in the context of HIV-1 diversity.Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbsHIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice.Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogenSequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloBinding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Selection on the human immunodeficiency virus type 1 proteome following primary infection.Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infectionA group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesA cationic nanoemulsion for the delivery of next-generation RNA vaccines.The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralizationEngineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Genetic Consequences of Antiviral Therapy on HIV-1.HIV DNA Vaccine: Stepwise Improvements Make a Difference.
P2860
Q21131325-50DEE8CE-3DFF-4823-BC79-6EF0DE913C3CQ21145682-4CD9E542-4352-443B-B6A9-C0F06C795C68Q22305973-863FCC0B-9A46-433C-970C-DF0FFA7573ACQ27489000-9884944B-8760-451D-A171-D0BCBC167A66Q28596371-DC1F5E47-32D7-4521-9FCA-DB59D94CDF4EQ28732043-C3EA25C0-533D-45D4-A7B0-9F331C350FAFQ28743092-7EBB7C05-7BCA-4477-B04D-2CC441EB4746Q28743767-1E699931-659E-494E-B890-D7269EE2FC0CQ29010789-3085817C-F7C3-47BC-9497-C01AC91FBEF0Q30379200-B246142A-3001-4827-BE65-B851A08B0777Q30410411-97CE087C-9689-4B9A-9037-6090E5D6184EQ30781299-FA028D33-4E1F-466B-950A-868746DCE4C2Q31148797-373277CD-F2AD-4CDA-8796-095F5DD023E3Q33283060-CA9DB285-87CE-45F4-A249-116054D41A0FQ33308246-CC92911B-FE39-4E9E-8C6E-A5937F044E2BQ33313394-74523A2F-2097-4DC3-B81B-DFC7793EE80AQ33642318-345BB749-A0A7-4F4A-A80D-C496B7781A13Q33648910-4796D05A-3FD4-41E0-8679-8D1AD4DC131FQ33664910-C3BD79AC-4CFA-4853-94F8-8A998879A78EQ33839456-BC451174-F79B-4DA4-A174-C4EC379149E0Q34023679-A4C72F53-10A5-400A-8AC8-898EA3D1D968Q34055984-14EEE4BA-8056-417F-98BE-EFC9261266BCQ34061970-A0EBE3FB-F2ED-4628-AD2A-32247C5CD36EQ34120873-E96832D6-A8B6-4E09-A486-067933A4CE85Q34388606-BF94AABC-AFD8-43BC-AF9E-554C55AFD039Q34423446-0BE0EA3A-0129-44A7-B5CD-F8F1F6DF238DQ34539819-3E09D1C2-AD95-47BF-BA42-3213D50CC274Q34653619-C29DA8EB-E9AC-464E-B58A-9802D97A6F29Q34717906-D1786850-B88E-4557-878A-BB97712D8906Q34982715-C0EC3B6B-57B5-4F7F-BBD5-B2E9C877D165Q35024202-86FE99B1-C019-431A-87AE-4AE9C1B10E48Q35077716-D2436D87-D1C5-4E40-9181-81A7EB60FC3CQ35101338-D26B2527-9D75-4890-8CDB-A10C3E125170Q35363127-C73FCA84-0CC7-4386-83E0-23F7030CB532Q35569049-83A5DDD0-A696-4391-A0EF-88481AD86CB8Q35600305-6F0BAEA6-89F5-4BD4-A185-513629D7A4BEQ35644971-EA15DF39-78ED-4BA8-9513-3E8D799075A5Q35666057-E5AC93C3-5506-464A-8BC7-C0C559E42F5FQ35773113-C12BF2E9-AF4A-43B4-B67E-7FFCDB62C1CEQ35826742-62ED119A-CEA7-431B-B378-76DC97859598
P2860
Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@ast
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@en
type
label
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@ast
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@en
prefLabel
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@ast
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@en
P2093
P2860
P3181
P1433
P1476
Human Immunodeficiency Virus T ...... Circulating Subtype B Envelope
@en
P2093
A. G. Rodrigo
D. C. Nickle
D. Montefiori
G. H. Learn
J. I. Mullins
M. Mahalanabis
M. T. Hensel
N. A. Doria-Rose
N. L. Haigwood
P2860
P304
11214-11224
P3181
P356
10.1128/JVI.79.17.11214-11224.2005
P577
2005-08-15T00:00:00Z